BioCentury | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXC chemokine receptor 1 (CXCR1); CXCR2 (IL8RB)

...Phase II testing for metastatic triple-negative breast cancer (TNBC) and renal transplant rejection. Dompe and SatRx LLC...
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); programmed cell death 1 (PD-1; PDCD1; CD279)

...and Phase II testing to treat breast cancer and prevent renal transplant rejection. Dompe and SatRx LLC...
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Inflammation

...this series, in preclinical testing for chronic obstructive pulmonary disease (COPD). Dompe Farmaceutici S.p.A. and SatRx LLC...
BioCentury | Jul 15, 2013
Company News

Dompe, SatRx LLC deal

...Dompe and SatRx partnered to develop and commercialize Dompe's Reparixin in Russia to improve liver transplantation...
...SatRx is responsible for conducting clinical trials and obtaining regulatory approval in Russia. Dompe said SatRx...
...to disclose details, and SatRx could not be reached. Dompe Farmaceutici S.p.A. , Milan, Italy SatRx LLC...
BioCentury | Jul 9, 2012
Company News

Pfizer, ChemRar deal

...Pfizer granted ChemRar's SatRx LLC company exclusive rights outside China to develop and commercialize Pfizer's gosogliptin...
BioCentury | Jul 6, 2012
Company News

Pfizer licenses diabetes compound to ChemRar

...Pfizer Inc. (NYSE:PFE) granted the SatRx company of ChemRar High Tech Center (Khimki, Russia) exclusive rights...
Items per page:
1 - 6 of 6
BioCentury | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXC chemokine receptor 1 (CXCR1); CXCR2 (IL8RB)

...Phase II testing for metastatic triple-negative breast cancer (TNBC) and renal transplant rejection. Dompe and SatRx LLC...
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); programmed cell death 1 (PD-1; PDCD1; CD279)

...and Phase II testing to treat breast cancer and prevent renal transplant rejection. Dompe and SatRx LLC...
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Inflammation

...this series, in preclinical testing for chronic obstructive pulmonary disease (COPD). Dompe Farmaceutici S.p.A. and SatRx LLC...
BioCentury | Jul 15, 2013
Company News

Dompe, SatRx LLC deal

...Dompe and SatRx partnered to develop and commercialize Dompe's Reparixin in Russia to improve liver transplantation...
...SatRx is responsible for conducting clinical trials and obtaining regulatory approval in Russia. Dompe said SatRx...
...to disclose details, and SatRx could not be reached. Dompe Farmaceutici S.p.A. , Milan, Italy SatRx LLC...
BioCentury | Jul 9, 2012
Company News

Pfizer, ChemRar deal

...Pfizer granted ChemRar's SatRx LLC company exclusive rights outside China to develop and commercialize Pfizer's gosogliptin...
BioCentury | Jul 6, 2012
Company News

Pfizer licenses diabetes compound to ChemRar

...Pfizer Inc. (NYSE:PFE) granted the SatRx company of ChemRar High Tech Center (Khimki, Russia) exclusive rights...
Items per page:
1 - 6 of 6